{
    "SPADE_N_13741": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13741",
            "Peptide Name": "Brevibacillin (Bre, natural AMPs; nonribosomal peptide; bogorol family, XXL; lipopeptide; XXw1; val-rich 31%; bacteria, prokaryotes)",
            "Source": "Brevibacillus laterosporus, OSY-I1",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "TLKIIVKVVKYLV",
            "Sequence Length": 13,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anti-MRSA",
                "Hemolytic"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 1515.96,
            "PI": 10.0,
            "Hydrophobicity": 1.52,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Yang X, Huang E, Yuan C, Zhang L, Yousef AE. 2016",
                    "Reference": "Appl Environ Microbiol. 2016 Apr 18;82(9):2763-2772. doi: 10.1128/AEM.00315-16.PubMed",
                    "Title": "Isolation and Structural Elucidation of Brevibacillin, an Antimicrobial Lipopeptide from Brevibacillus laterosporus That Combats Drug-Resistant Gram-Positive Bacteria."
                }
            ],
            "Frequent Amino Acids": "VKI",
            "Absent Amino Acids": "ACDEFGHMNOPQRSUW",
            "Basic Residues": 3,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 9,
            "Polar Residues": 9,
            "Positive Residues": 3,
            "Negative Residues": 0,
            "Net Charge": 3,
            "Comments": "Sequence analysis:  APD analysis reveals this sequence is most similar (92.31%) toBogorol LSequence similarity: Leu2 in brevibacillin is replaced by Val2 in bogorol K.Chemical modification:  T1 dehydrated (XXW); K3=ornithine; N-terminus is acylated with 2-hydroxy-3-methylvaleric acid (lipo).Activity:  Active against Gram+ A. acidoterrestris, A. acidoterrestris ATCC 49025 (MIC 0.5-1.0 ug/ml),  B. cereus ATCC 11778 (MIC 2-4 ug/ml), B. cereus ATCC 14579 (MIC 1.0 ug/ml), C. difficile A515 (MIC 4-8 ug/ml), E. faecalis ATCC 29212 (MIC 2 ug/ml), E. faecalis ATCC 51299 anti-VRE (MIC 4-8 ug/ml), L. plantarum ATCC 8014 (MIC 2 ug/ml), L. lactis ATCC 11454 (MIC 2 ug/ml), L. innocua ATCC 33090 (MIC 1-2 ug/ml), L. monocytogenes OSY-8578 (MIC 1-2 ug/ml), L. monocytogenes Scott A (MIC 1 ug/ml), S. aureus ATCC 6538, MRSA (MIC 1-2 ug/ml), Gram- E-coli K-12 (MIC >32 ug/ml), E. coli O157:H7 EDL 933 (MIC 32 ug/ml), P-aeruginosa ATCC 27853, S-enterica serovar Typhimurium DT 109 (MIC >32 ug/ml). Also active against X. campestris pv. campestris NCCB92058 (MIC 2 ug/ml), X. translucens pv. graminis LMG587 (MIC 2 ug/ml), P. syringae pv. antirrhini LMG2131, P. syringae pv. tomato DC3000 (MIC 8-16 ug/ml), P. aeruginosa PAO1 (MIC 32), K. pneumoniae LMG20218 (MIC 16 ug/ml), E. coli ET8 or MG1665 (MIC 8-16 ug/ml), P.carotovorum LMG5863 (ND), R. syzygii subsp. syzygii LMG6969 (ND), S. aureus subsp. aureus 533 R4, B. cereus ATCC 14579, E. faecium LMG16003 (MIC 1-2) (Data from ref for Bogorol K). Also, Active against Gram+ S. aureus ATCC15975 (MRSA) (MIC 2 ug/ml), E. faecium LMG16003 (VRE), E. faecalis LMG16216 (VRE), B. cereus ATCC14579 (MIC 1-2 ug/ml), Gram- A. baumannii ATCC17978 (MIC 32 ug/ml), E. coli ATCC25922 (MIC 32 ug/ml), P. aeruginosa LMG6395 (MIC 64 ug/ml), and K. pneumoniae LMG20218 (MIC 32 ug/ml).MOA:  binds to lipoteichoic acid and then disrupts cytoplasmic membrane of S. aureus (Yang et al. 2017).Antimicrobial robustness:  Purified brevibacillin showed no degradation at 80Â°C for 60 min, and retained at least 50% of its activity under acidic or alkaline conditions for 22 h.Toxicity:  highly hemolytic: HC50=25.1 ug/ml and toxic: IC50 of HepG2 cells is 5.21 ug/ml.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_13742",
                    "Similarity": 0.9230769230769231,
                    "Sequence": "TLKIVVKVVKYLV"
                },
                {
                    "SPADE_ID": "SPADE_N_13744",
                    "Similarity": 0.9230769230769231,
                    "Sequence": "TLKIIVKIVKYLV"
                },
                {
                    "SPADE_ID": "SPADE_N_13740",
                    "Similarity": 0.9230769230769231,
                    "Sequence": "TVKIIVKVVKYLV"
                }
            ]
        }
    }
}